Лабораторные биомаркеры анкилозирующего спондилита

Автор: Александрова Е.Н., Новиков А.А.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Обзоры

Статья в выпуске: 1 т.55, 2017 года.

Бесплатный доступ

Анкилозирующий спондилит (АС) - хроническое воспалительное заболевание из группы спондилоартритов (СпА), характеризующееся поражением крестцово-подвздошных суставов и позвоночника с частым вовлечением в патологический процесс энтезисов и периферических суставов. Достижения современной лабораторной медицины способствовали существенному расширению спектра патогенетических, диагностических и прогностических биомаркеров АС. В настоящее время выделены ключевые патогенетические биомаркеры АС (терапевтические «мишени»), к которым относятся фактор некроза опухоли а (ФНОа), интерлейкин 17 (ИЛ17) и ИЛ23. Среди диагностических и прогностических лабораторных биомаркеров АС наибольшее значение в клинической практике имеют HLA-B27 (для ранней диагностики заболевания) и С-реактивный белок (СРБ; для оценки активности, риска рентгенологического прогрессирования и эффективности терапии). Новым биомаркером, позволяющим с высокой чувствительностью и специфичностью осуществлять диагностику аксиального СпА на ранней стадии, являются антитела к CD74. Ряд лабораторных биомаркеров, включая кальпротектин, матриксную металлопротеиназу 3 (ММП3), васкуло-эндотелиальный фактор роста, Dickkopf-1 (Dkk-1) и С-терминальный телопептид коллагена II типа (CTX II), недостаточно хорошо отражают активность заболевания, но могут быть предикторами прогрессирования структурных изменений позвоночника и крестцово-подвздошных сочленений при АС. Мониторинг уровня кальпротектина в крови позволяет эффективно прогнозировать ответ на терапию ингибиторами ФНОа и моноклональными антителами к ИЛ17А. Перспективы лабораторной диагностики АС связаны с клинической валидацией кандидатных биомаркеров в ходе больших проспективных когортных исследований и поиском новых протеомных, транскриптомных и геномных маркеров на основе инновационных молекулярно-клеточных технологий.

Еще

Анкилозирующий спондилит, аксиальный спондилоартрит, генетические полиморфизмы, аутоантитела, маркеры воспаления, цитокины, факторы ангиогенеза, маркеры ремоделирования костной и хрящевой ткани

Короткий адрес: https://readera.org/14945800

IDR: 14945800   |   DOI: 10.14412/1995-4484-2017-96-103

Список литературы Лабораторные биомаркеры анкилозирующего спондилита

  • Эрдес ШФ. Развитие концепции спондилоартритов. Научнопрактическая ревматология. 2014; 52(5): 474-6
  • Van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 1984; 27(3): 241-9 DOI: 10.1002/art.1780270301
  • Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun. 2014; 48-49: 128-33 DOI: 10.1016/j.jaut.2014.01.015
  • Prajzlerova K, Grobelna K, Pavelka K, et al. An update on biomarkers in axial spondyloarthritis. Autoimmun Rev. 2016; 15(6): 501-9 DOI: 10.1016/j.autrev.2016.02.002
  • Reveille JD. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol. 2015; 34(6): 1009-18 DOI: 10.1007/s10067-015-2949-3
  • Maksymowych WP Biomarkers in axial spondiloarthritis. Curr Opin Rheumatol. 2015; 27: 343-8 DOI: 10.1097/BOR.0000000000000180
  • Navarro-Compan V, Ramiro S, Landewe R, et al. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Ann Rheum Dis. 2016; 75(5): 874-8 DOI: 10.1136/annrheumdis-2015-207786
  • Эрдес ШФ, Дубинина ТВ, Абдулганиева ДЭ и др. Клиническая характеристика анкилозирующего спондилита в реальной практике в России: результаты одномоментного многоцентрового неинтервенционного исследования ЭПИКА2. Научно-практическая ревматология. 2016; 54(Прил 1): 10-4
  • McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoSMed. 2006; 3(8): e297 DOI: 10.1371/journal.pmed.0030297
  • Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004; 63(5): 535-43 DOI: 10.1136/ard.2003.011247
  • Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4): 361-8 DOI: 10.1002/art.1780270401
  • Rudwaleit M, Landewe R, van der Heijde D, et al. The development of Assessment of Spondylo Arthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009; 68(6): 770-6 DOI: 10.1136/ard.2009.108217
  • Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of Spondylo Arthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68(6): 777-83 DOI: 10.1136/ard.2009.108233
  • Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011; 70(8): 1369-74 DOI: 10.1136/ard.2010.145995
  • Pedersen SJ, Sorensen IJ, Lambert RG, et al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor а inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum. 2011; 63(12): 3789-800 DOI: 10.1002/art.30627
  • Maneiro JR, Souto A, Salgado E, et al. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 2015; 1: e000017 DOI: 10.1136/rmdopen-2014-000017
  • Baraliakos X, Baerlecken N, Witte T, et al. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis. 2014; 73(6): 1079-82 DOI: 10.1136/annrheumdis-2012-202177
  • Baerlecken NT, Nothdorft S, Stummvoll GH, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis. 2014; 73(6): 1211-4 DOI: 10.1136/annrheumdis-2012-202208
  • Александрова ЕН, Новиков АА, Насонов ЕЛ. Рекомендации по лабораторной диагностике ревматических заболеваний Общероссийской общественной организации «Ассоциация ревматологов России» -2015. Современная ревматология. 2015; 9(4): 25-36
  • Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009; 60(3): 717-27 DOI: 10.1002/art.24483
  • De Vries MK, van Eijk IC, van der Horst-Bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 2009; 61(11): 1484-90 DOI: 10.1002/art.24838
  • Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999; 26(4): 980-4.
  • Yildirim K, Erdal A, Karatay S, et al. Relationship between some acute phase reactants and the Bath Ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis. South Med J. 2004; 97(4): 350-3 DOI: 10.1097/01.SMJ.0000066946.56322.3C
  • Wallis D, Haroon N, Ayearst R, et al. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases? J Rheumatol. 2013; 40(12): 2038-41 DOI: 10.3899/jrheum.130588
  • Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012; 64(5): 1388-98 DOI: 10.1002/art.33465
  • Costenbader KH, Chibnik LB, Schur PH. Discordance between erythrocyte sedimentation rate and C-reactive protein measurements: clinical significance. Clin Exp Rheumatol. 2007; 25: 746-9.
  • Poddubnyy DA, Rudwaleit M, Listing J, et al. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2010; 69(7): 1338-41 DOI: 10.1136/ard.2009.120139
  • Pedersen SJ, Sorensen IJ, Garnero P, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF? inhibitors. Ann Rheum Dis. 2011; 70(8): 1375-81 DOI: 10.1136/ard.2010.138883
  • Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis. 2008; 67(4): 511-7 DOI: 10.1136/ard.2007.071605
  • Румянцева ОА, Бочкова АГ, Логинова ЕЮ и др. Влияние терапии инфликсимабом на лабораторные маркеры воспаления у больных анкилозирующим спондилитом. Эффективная фармакотерапия. 2011; (40): 22-8
  • Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum. 2008; 58(3): 649-56 DOI: 10.1002/art.23260
  • Eklund KK, Niemi K, Kovanen PT. Immune functions of serum amyloid A. Crit Rev Immunol. 2012; 32(4): 335-48 DOI: 10.1615/CritRevImmunol.v32.i4.40
  • Lange U, Boss B, Teichmann J, et al. Serum amyloid A-an indicator of inflammation in ankylosing spondylitis. Rheumatol Int. 2000; 19(4): 119-22 DOI: 10.1007/s002960050114
  • Jung SY, Park MC, Park YB, Lee SK. Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J. 2007; 48(2): 218-24 DOI: 10.3349/ymj.2007.48.2.218
  • Vogl T, Tenbrock K, Ludvig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxine-induced shock. Nat Med. 2007; 13: 1042-9 DOI: 10.1038/nm1638
  • Turina MC, Yeremenko N, Paramatra JE, et al. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014; 16: 413 DOI: 10.1186/s13075-014-0413-4
  • Cypers H, Varkas G, Beeckman S, et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2015; 0: 1-6 DOI: 10.1136/annrheumdis-2015-208025
  • Oktayoglu P, Bozkurt M, Mete N, et al. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 2014; 62: 880-4 DOI: 10.1097/JIM.0000000000000095
  • Turina MC, Sieper J, Yeremenko N, et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis. 2014; 73: 1746-8 DOI: 10.1136/annrheumdis-2014-205506
  • Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009; 229: 12-26 DOI: 10.1111/j.1600-065X.2009.00770.x
  • Toussirot E, Saas P, Deschamps M, et al. Increased production of soluble CTLA-4 in patients with spondyloarthropathies correlates with diseases activity. Arthritis Res Ther. 2009; 11: R101 DOI: 10.1186/ar2747
  • Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011; 70: 1108-10 DOI: 10.1136/ard.2010.145946
  • Davis JC Jr. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin Athritis Rheum. 2005; 34: 668-77 DOI: 10.1016/j.semarthrit.2004.08.005
  • Braun J, Baraliakos X, Heldmann F, Kiltz U. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. Expert Opin Investig Drug. 2014; 23: 647-59 DOI: 10.1517/13543784.2014.899351
  • Sherlock JP, Taylor PC, Buckley CD. The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases. Curr Opin Rheumatol. 2015; 27: 71-5 DOI: 10.1097/B0R.0000000000000132
  • Xueyi L, Lina C, Zhenbao W, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-alpha therapy. J Clin Immunol. 2013; 33: 151-61 DOI: 10.1007/s10875-012-9774-0
  • Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994; 33: 927-31 DOI: 10.1093/rheumatology/33.10.927
  • Neumann E, Junker S, Schett G, et al. Adipokines in bone disease. Nat Rev Rheumatol. 2016; 12(5): 296-302 DOI: 10.1038/nrrheum.2016.49
  • Syrbe U, Callhoff J, Conrad K, Poddubnyy D, et al. Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression. Arthritis Rheum. 2015; 67(3): 678-85 DOI: 10.1002/art.38968
  • Park MC, Lee SW, Choi ST, et al. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol. 2007; 36(2): 101-6 DOI: 10.1080/03009740600991760
  • Kim KJ, Kim JY, Park SJ, et al. Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis. Clin Rheumatol. 2012; 31(8): 1231-8 DOI: 10.1007/s10067-012-1999-z
  • Pedersen SJ, Hetland ML, Sorensen IJ, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFа inhibitors. Clin Rheumatol. 2010; 29(11): 1301-9 DOI: 10.1007/s10067-010-1528-x
  • Drouart M, Saas P, Billot M, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol. 2003; 132(1): 158-62 DOI: 10.1046/j.1365-2249.2003.02101.x
  • Appel H, Janssen L, Listing J, et al. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther. 2008; 10(5): R125 DOI: 10.1186/ar2537
  • Poddubnyy D, Conrad K, Haibel H, et al. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis. 2014; 73(12): 2137-43 DOI: 10.1136/annrheumdis-2013-203824
  • Christgau S, Garnero P, Fledelius C, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone. 2001; 29(3): 209-15 DOI: 10.1016/S8756-3282(01)00504-X
  • Park MC, Chung SJ, Park YB, Lee SK. Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis. Yonsei Med J. 2008; 49(2): 288-
  • Vosse D, Landewe R, Garnero P, et al. Association of markers of bone-and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology (Oxford). 2008; 47(8): 1219-22 DOI: 10.1093/rheumatology/ken148
  • Maksymowych WP, Rahman P, Shojania K, et al. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol. 2008; 35(10): 2030-7.
  • Bay-Jensen AC, Wichuk S, Byrjalsen I, et al. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS One. 2013; 8(1): e54504 DOI: 10.1371/journal.pone.0054504
  • Visvanathan S, van der Heijde D, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009; 68(2): 175-82 DOI: 10.1136/ard.2007.084426
  • Arends S, Spoorenberg A, Efde M, et al. Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a crosssectional analysis. PLoS One. 2014; 9(6): e99685 DOI: 10.1371/journal.pone.0099685
  • Wendling D, Cedoz JP, Racadot E. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy. Joint Bone Spine. 2008; 75(5): 559- DOI: 10.3349/ymj.2008.49.2.288
  • Neidhart M, Baraliakos X, Seemayer C, et al. Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis. Ann Rheum Dis. 2009; 68(8): 1334-9 DOI: 10.1136/ard.2008.092494
  • Choi ST, Kim JH, Kang EJ, et al. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford). 2008; 47(12): 1775-9 DOI: 10.1093/rheumatology/ken385
  • Pinzone JJ, Hall BM, Thudi NK, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009; 113(3): 517-25 DOI: 10.1182/blood-2008-03-145169
  • Kwon SR, Lim MJ, Suh CH, et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int. 2012; 32(8): 2523-7 DOI: 10.1007/s00296-011-1981-0
  • Daoussis D, Liossis SN, Solomou EE, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 2010; 62(1): 150-8 DOI: 10.1002/art.27231
  • Heiland GR, Appel H, Poddubnyy D, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012; 71(4): 572-4 DOI: 10.1136/annrheumdis-2011-200216
  • Poole KE, van Bezooijen RL, Loveridge N. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19(13): 1842-4 DOI: 10.1096/fj.05-4221fje
  • Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009; 60(11): 3257-62 DOI: 10.1002/art.24888
  • Saad CG, Ribeiro AC, Moraes JC, et al. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther. 2012; 14(5): R216 DOI: 10.1186/ar4055
  • Mattey DL, Packham JC, Nixon NB, et al. Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res Ther. 2012; 14(3): R127 DOI: 10.1186/ar3857
  • Maksymowych WP, Landewe R, Conner-Spady B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 2007; 56(6): 1846-53 DOI: 10.1002/art.22589
  • Bay-Jensen AC, Karsdal MA, Vassiliadis E, et al. Circulating cit-rullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression. Arthritis Rheum. 2013; 65(4): 972-80 DOI: 10.1002/art.37843
  • Chandra PE, Sokolove J, Hipp BG, et al. Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther. 2011; 13(3): R102 DOI: 10.1186/ar3383
  • Wagner C, Visvanathan S, Braun J, et al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Ann Rheum Dis. 2012; 71: 674-80 DOI: 10.1136/ard.2010.148890
Еще
Статья обзорная